Home › Diffuse Large B-Cell Lymphoma › Montana

Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa Montana

3 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Montana.

Opisyal na teksto ng pag-aaral (English)

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0178), Billings

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT06717347

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Bozeman Health Deaconess Hospital ( Site 0183), Bozeman

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT06890884

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Billings Clinic Cancer Center, Billings
Benefis Sletten Cancer Institute, Great Falls
Community Medical Center, Missoula

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT06649812

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.